Company Profile

Saphtx Inc
Profile last edited on: 12/14/21      CAGE: 87NK9      UEI: MBANWG4RJ2E9

Business Identifier: Protein-based therapeutic strategies for treatment of variety of diseases: self-assembling peptide hydrogel technologies
Year Founded
2018
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

136 4th Avenue
Newark, NJ 07104
   (973) 943-8314
   info@saphtx.com.
   www.saphtx.com
Location: Single
Congr. District: 08
County: Essex

Public Profile

A team of engineers and biologists, Saphtx is structured around developing protein-based therapeutic strategies to address some important, currrent health issues. Approach is to address molecular design —> pan-coronavirus peptide drug —> Intranasal Spray to treat COVID-19 and variants. To date, the target has been defined (evolving Spike); a protein (peptide) that binds Spike has been designed. Drug has been characterized the drug and proven to work - blocking live-virus in vitro. Animal testing underway. Funds being raised to take this to clinic (GMP manufacturing and large animal DMPK). In the current context (late 2021), principals note that NO APPROVED DRUG exists for COVID-109 treatment outside hospital setting. Noting that re-purposed drugs have shown some clinical benefit, but have limitations, and are NOT APPOVED to treat non-hospitalized COVID-19 patients - Saphtx personnel are (currently) developing a rapidly scalable, cost-effective technology that is shown to block COVID-19 infection by “binding” or attaching specifically to SARS-CoV-2 and blocking its entry into human cells. Management suggest that the peptides (small proteins) theyare studying act like antibodies or complements what the human body naturally produces - binding to the SARS-CoV-2 virus, and targeting it for destruction. The hope is to create a safe and inexpensive therapeutic that will help reduce the spread and increase accessibility of treatment for CO

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NSF $255,933
Project Title: Designer peptide opsonins against COVID-19

Key People / Management

  Corey Heffernan -- CEO and CSO

  Vivek Kumar -- Founder & Chief Executive Officer

  Jonathan Aslam -- Chief Financial Officer

Company News

There are no news available.